Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Pancreatic Neoplasms 199Breast Neoplasms 111Carcinoma, Non-Small-Cell Lung 94Triple Negative Breast Neoplasms 66Neoplasm Metastasis 44Neoplasms 42Lung Neoplasms 25Squamous Cell Carcinoma of Head and Neck 24Colorectal Neoplasms 18Stomach Neoplasms 17Esophageal Squamous Cell Carcinoma 17Adenocarcinoma 17Melanoma 15Head and Neck Neoplasms 15Ovarian Neoplasms 12Cholangiocarcinoma 11Carcinoma 11Parkinson Disease 4, Autosomal Dominant Lewy Body 10Gallbladder Neoplasms 10Esophageal Neoplasms 10Carcinoma, Pancreatic Ductal 10Small Cell Lung Carcinoma 9Sarcoma 9Fallopian Tube Neoplasms 9Biliary Tract Neoplasms 9Carcinoma, Squamous Cell 8Neoplasms by Site 7Pancreatic Diseases 6Pancreatic Adenocarcinoma 6Digestive System Neoplasms 6

Interventions

camrelizumab 1apatinib 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Locally Advanced or Metastatic Gastric Adenocarcinoma × 130-nm albumin-bound paclitaxel × Clear all
NCT04572542 2020-10-01

Camrelizumab Combined With Apatinib Mesylate Tablets and Nab-paclitaxel in the Second-line Treatment of Advanced Gastric Cancer

The First Affiliated Hospital of Xiamen University

Phase 1/2 Unknown
46 enrolled
Gastrointestinal

Locally Advanced or Metastatic Gastric Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡